Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First is scheduled to end on July 31st. Click the link below to learn about your options for continuing care at Temple Health.

Learn More
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Phase 2a Randomized, Doubled-Blind, Placebo-Controlled Trial to Evaluate Safety, Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of RLS-0071 in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

view all Clinical Trials

Overview

The Phase 2 clinical trial will be a randomized, double-blind, placebo-controlled trial in hospitalized patients with AE-COPD. Patients will receive either RLS-0071 or placebo as an add-on to standard of care therapy.

Clinical Trial Information

Phase

2

Condition(s)

Chronic Obstructive Pulmonary Disease (COPD)

Investigator

Gerard Criner, MD

Coordinator

Dave Miller

Contact

For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.

Related Clinical Trials

Biological Effects of Quercetin in COPD Phase II (polyphenols)

TIRB# 25738
  • Conditions: Chronic Obstructive Pulmonary Disease (COPD)
  • Investigator: Nathaniel Marchetti, DO
  • Coordinator: Sara Khademolhosseini
View Details

Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation

TIRB# 29791
  • Conditions: Chronic Obstructive Pulmonary Disease (COPD)
  • Investigator: Gerard Criner, MD
  • Coordinator: David Miller
View Details

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

TIRB# 31322
  • Conditions: Idiopathic Pulmonary Fibrosis (IPF), Pulmonary Fibrosis (Including IPF), Interstitial Lung Disease (ILD)
  • Investigator: Gerard Criner, MD
  • Coordinator: Debasree Sana Boral
View Details